Objectives:
In this study, we assessed the relationship between pain scores and the pathology results of patients who underwent transrectal ultrasound-guided prostate biopsy (TRUS-PBx).
Materials and Methods:
A total of 198 patients who underwent prostate biopsy between October 2014 and April 2015 due to abnormal digital rectal examination findings and/or high prostate-specific antigen (PSA) levels (≥2.5 ng/dL) were included in this study. Before the biopsy procedure, all patients underwent finger-guided transperineal periprostatic block with 10 mL of 2% prilocaine. A 10-point linear visual analogue scale (VAS) was used to assess the pain arising from probe insertion (VAS-1) and prostate sampling (VAS-2). After receiving the pathology results, the patients were grouped according to the presence of prostate cancer: Group 1: patients without prostate cancer and Group 2: patients with prostate cancer.
Results:
The mean age of the patients was 64±7.3 (43-83) years, and the mean PSA value was 12.5±18.3 (0.6-142) ng/dL. Prostate cancer detection rate was 22.7%. The mean VAS-1 score in Group 1 and group 2 was 1.6±1.8 and 2.0±2.5, respectively (p=0.209). The mean VAS-2 score in Group 1 and Group 2 was 2.5±2.4 and 2.6±2.6, respectively (p=0,725).
Conclusion:
The pain felt during TRUS-PBx is not related with the presence of prostate cancer on biopsy pathology.
Keywords: Prostate-specific antigen, biopsy, pain, prostate